95% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Pharmacology of Infectious Diseases
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1554370
This article is part of the Research Topic ADME of Drugs to Treat Infectious Diseases View all 8 articles
Population Pharmacokinetics and Dose Optimization of Voriconazole in Patients with COVID-19-Associated Pulmonary Aspergillosis
Provisionally accepted- 1 Nanjing Drum Tower Hospital, Nanjing, China
- 2 The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
The study aimed to investigate the pharmacokinetic profile of voriconazole in patients with COVID-19-associated pulmonary aspergillosis (CAPA) to optimize dosing strategies.Methods: Population pharmacokinetic modeling was conducted using clinical data from CAPA patients to analyze voriconazole's pharmacokinetic behavior. A one-compartment model with first-order elimination was employed to characterize voriconazole disposition. Covariate analysis was further utilized to evaluate the impact of continuous renal replacement therapy (CRRT) and select biochemical markers on voriconazole clearance.The model estimated voriconazole's apparent clearance (CL/F) at 3.17 L/h and apparent volume of distribution (V/F) at 135 L for a standard patient with CAPA.Covariates such as CRRT, C-reactive protein, gamma-glutamyl transpeptidase, aspartate aminotransferase, and platelet count were found to significantly influence voriconazole clearance. Monte Carlo simulations indicated that patients on CRRT required both a higher loading dose and an increased maintenance dose compared to those not on CRRT.This study provides an evidence-based guide for voriconazole dosing adjustments in CAPA patients, particularly for those undergoing CRRT. The findings emphasize the importance of individualized dosing to improve therapeutic outcomes in this high-risk population.
Keywords: COVID-19-associated pulmonary aspergillosis, Voriconazole, population pharmacokinetics, dosage optimization, monte carlo
Received: 02 Jan 2025; Accepted: 14 Mar 2025.
Copyright: © 2025 Wang, Shen, Luo, Jin, Zhu and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Huaijun Zhu, Nanjing Drum Tower Hospital, Nanjing, China
Jing Wang, Nanjing Drum Tower Hospital, Nanjing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.